US Stock MarketDetailed Quotes
CLRB Cellectar BioSciences
- 1.5800
- +0.0200+1.28%
Close Nov 21 16:00 ET
- 1.5500
- -0.0300-1.90%
Post 20:01 ET
65.21MMarket Cap-1120P/E (TTM)
1.5950High1.3850Low1.35MVolume1.5800Open1.5600Pre Close2.02MTurnover4.41%Turnover RatioLossP/E (Static)41.27MShares4.450052wk High41.58P/B48.25MFloat Cap1.385052wk Low--Dividend TTM30.54MShs Float13678193.1609Historical High--Div YieldTTM13.46%Amplitude1.2500Historical Low1.5020Avg Price1Lot Size
Cellectar BioSciences Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -13.62%-9.17M | -87.80%-14.14M | -86.00%-13.36M | -28.37%-32.38M | -29.47%-9.6M | -15.04%-8.07M | -30.78%-7.53M | -42.54%-7.18M | -11.76%-25.22M | -64.30%-7.41M |
| Net income from continuing operations | 16.30%-14.66M | 90.97%-919.37K | -270.52%-26.64M | -32.80%-37.98M | 57.12%-3.09M | -124.29%-17.52M | -36.90%-10.18M | -17.11%-7.19M | -18.57%-28.6M | -21.92%-7.22M |
| Operating gains losses | -79.71%1.65M | -736.32%-12.46M | 1,175.67%14.96M | -15,752.69%-530K | ---9.25M | --8.16M | --1.96M | ---1.39M | 15.29%3.39K | --0 |
| Depreciation and amortization | 66.40%68.57K | 70.82%66.02K | 107.93%88.49K | 29.60%192.38K | 83.34%69.96K | 25.02%41.21K | 14.02%38.65K | -1.98%42.56K | -0.99%148.44K | -2.88%38.16K |
| Other non cash items | 13.00%16.65K | ---- | ---- | -35.81%58.05K | -36.01%15.28K | -35.98%14.73K | ---- | ---- | 16.35%90.43K | 16.17%23.89K |
| Change In working capital | 200.23%2.22M | -910.94%-1.66M | -334.77%-2.22M | 106.43%3.48M | 355.30%1.58M | 97.82%740.65K | -82.88%205.06K | 29.45%946.83K | 747.12%1.68M | -163.97%-620.16K |
| -Change in prepaid assets | 160.08%400.64K | -193.65%-699.27K | 8.14%-448.96K | -184.97%-173.55K | -24.77%235.24K | -34.36%-666.79K | 165.97%746.72K | -556.47%-488.72K | 319.49%204.24K | 73.14%312.69K |
| -Change in payables and accrued expense | 29.39%1.84M | -81.48%-930.74K | -225.14%-1.78M | 127.91%3.7M | 253.51%1.36M | 57.27%1.42M | -153.96%-512.87K | 117.13%1.43M | 294.33%1.62M | -208.31%-888.59K |
| -Change in other current liabilities | -16.94%-18.11K | -16.94%-17.49K | -5.96%-4.64K | 64.70%-50.85K | 63.78%-16.03K | 54.58%-15.48K | 55.03%-14.95K | 86.50%-4.38K | -20.13%-144.04K | -39.92%-44.26K |
| -Change in other working capital | ---- | ---- | 11.62%15.44K | ---- | ---- | ---- | ---- | --13.83K | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -13.62%-9.17M | -87.80%-14.14M | -86.00%-13.36M | -28.37%-32.38M | -29.47%-9.6M | -15.04%-8.07M | -30.78%-7.53M | -42.54%-7.18M | -11.76%-25.22M | -64.30%-7.41M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 0 | -21.28K | -21.63K | -282.37%-864.04K | -126.34%-266.76K | -8,352.90%-597.28K | 0 | 0 | -59.85%-225.97K | 9.16%-117.86K |
| Net PPE purchase and sale | --0 | ---21.28K | ---21.63K | -282.37%-864.04K | -126.34%-266.76K | -8,352.90%-597.28K | --0 | --0 | -59.85%-225.97K | 9.16%-117.86K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | --0 | ---21.28K | ---21.63K | -282.37%-864.04K | -126.34%-266.76K | -8,352.90%-597.28K | --0 | --0 | -59.85%-225.97K | 9.16%-117.86K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -21.94%17.56M | 1 | 1,461,648,800.00%43.85M | 138.69%22.94M | -95.41%441K | 22.5M | 0 | 3 | 669.59%9.61M | 961,065,600.00%9.61M |
| Net preferred stock issuance | ---- | ---- | ---- | 130.47%22.15M | --0 | ---- | ---- | ---- | --9.61M | --9.61M |
| Proceeds from stock option exercised by employees | 4,937.13%17.56M | --1 | 1,461,648,800.00%43.85M | --789.64K | --441K | --348.64K | --0 | --3 | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -21.94%17.56M | --1 | 1,461,648,800.00%43.85M | 138.69%22.94M | -95.41%441K | --22.5M | --0 | --3 | 669.59%9.61M | 961,065,600.00%9.61M |
| Net cash flow | ||||||||||
| Beginning cash position | 402.02%25.87M | 215.64%40.03M | -51.85%9.56M | -44.36%19.87M | 6.75%18.99M | -79.23%5.15M | -58.60%12.68M | -44.36%19.87M | -37.54%35.7M | -55.92%17.79M |
| Current changes in cash | -39.32%8.39M | -88.09%-14.16M | 524.10%30.47M | 34.96%-10.3M | -552.73%-9.42M | 297.05%13.83M | -29.19%-7.53M | -41.69%-7.18M | 26.20%-15.84M | 144.84%2.08M |
| End cash Position | 80.46%34.26M | 402.02%25.87M | 215.64%40.03M | -51.85%9.56M | -51.85%9.56M | 6.75%18.99M | -79.23%5.15M | -58.60%12.68M | -44.36%19.87M | -44.36%19.87M |
| Free cash flow | -5.79%-9.17M | -88.09%-14.16M | -86.30%-13.38M | -30.62%-33.24M | -30.98%-9.86M | -23.43%-8.67M | -29.19%-7.53M | -41.69%-7.18M | -12.06%-25.45M | -62.25%-7.53M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data